1:30 – 4:30 p.m.
Cocktail reception to follow
Please join us and cannabis industry experts in an engaging discussion around the legal considerations and solutions of the cannabis and CBD industry.
Featured Regulatory Panelist Amanda Ostrowitz, CEO, CannaRegs
Cannabis and CBD and Due Diligence: Legal Considerations and Solutions Panelists
 John DarwinPresident One Cannabis |  Matt HawkinsFounder/Managing Partner Entourage Effect Capital |
 Elena MervineSenior Manager CohnReznick |  Steve ErnestDirector of Business Development Virdian Capital Advisors |
 Kate W. HardeyPartner McGuireWoods LLP (Moderator) |  Royce B. DuBinerAttorney McGuireWoods LLP (Moderator) |
Who Should Attend
This McGuireWoods symposium will bring together healthcare executives with healthcare providers, lenders, investors, board members and entrepreneurs from many industry niches:
- Physicians, hospitals and health systems
- Private equity funds
- Lenders and investors
- Pharmaceutical manufacturers
- Cannabis businesses
Disclaimer: Cannabis is still classified as a Schedule I controlled substance by the U.S. Drug Enforcement Agency, and, as such, it remains a federal crime to grow, sell, and/or use cannabis. Any content contained herein is not intended to provide legal advice to assist with the violation of any state or federal law.
Our programs are intended for the benefit of our clients and contacts and we reserve the right to refuse any registration at our sole discretion.